(.pdf) dr.ssa Antonella Ferro - Progettoeventi
(.pdf) dr.ssa Antonella Ferro - Progettoeventi (.pdf) dr.ssa Antonella Ferro - Progettoeventi
Trastuzumab + Pertuzumab
Trastuzumab binds to subdomain IV of HER2, continually suppresses HER2 activity and flags cells for destruction by the immune system angiogenesis RAS Sos Grb2 Shc Raf MEK MAPK HER2 mTOR PI3K Cyclin D1 cell cycle control proliferation HER2 p27 PDK1 BAD AKT NFκB ↓ apoptosis GSK3β ↑ survival
- Page 1 and 2: Utilizzo dei farmaci nei diversi co
- Page 3 and 4: HER2 positive breast cancer “Targ
- Page 5 and 6: Trastuzumab (Herceptin) • Il Tras
- Page 7 and 8: Trastuzumab binds to ErbB2 on tumou
- Page 9 and 10: Antibody-Dependent Cellular Cytotox
- Page 11 and 12: Potenziale meccanismo di trastuzuma
- Page 13: Malattia adiuvante
- Page 17 and 18: DFS: Sequential (Arm B: AC → T
- Page 19 and 20: Malattia Neo- adiuvante
- Page 21 and 22: Studio NOAH: Event Free Survival ne
- Page 23 and 24: Trastuzumab has transformed the pro
- Page 25 and 26: Definition of resistance In most tu
- Page 27 and 28: Truncated HER2 (p95 HER2 ): clinica
- Page 29 and 30: Trastuzumab Capecitabine von Minckw
- Page 31 and 32: GBG 26/BIG 03-05: main results Cape
- Page 33 and 34: Phase III, randomised, controlled s
- Page 35 and 36: Lapatinib • Binds to intracellula
- Page 37 and 38: Lapatinib may sensitise HER2 positi
- Page 39 and 40: Pertuzumab • Pertuzumab, inibitor
- Page 41: HER2 dimerization is key to signali
- Page 45 and 46: Trastuzumab and pertuzumab may have
- Page 47 and 48: Receptor-T-DM1 complex is internali
Trastuzumab +<br />
Pertuzumab